Conversing and collaborating to the point where imagination expands is the work of Design to Value..

This collaboration is intended to reduce costs, enhance sustainability, and ultimately accelerate the production and accessibility of essential medicines.The event highlighted both the opportunities and obstacles to implementing new manufacturing technologies and provided a space for companies to strategise solutions to industry-wide challenges.. 4.

Industrialisation as a catalyst for carbon reduction.Jaimie emphasised that industrialisation, particularly when guided by sustainability goals, has the power to reshape industries and reduce carbon footprints.Smaller, modular facilities and continuous processing offer more than operational efficiency—they represent a pathway to decarbonise manufacturing processes on a global scale, achieving high-impact results in less time..

Learn more about our.Design to Value.Jaimie talked about the transformative advancements in data centre design and delivery, emphasising how innovative design principles and industrialised construction are setting a new standard across industries.

to watch the full session on Autodesk's website.. Key Takeaways.

Scaling for AI-Ready data centres.Pharmaceutical manufacturing of a single product through its lifecycle spans multiple functions and sites within each organisation and spans multiple organisations through product acquisitions and contract manufacturing.

Thus, the breadth of what needs to be changed to deploy a new platform technology is significant.. Resistance to challenging accepted practice.Regulatory and patient safety risks are always high up the agenda for the pharmaceutical industry.

The unfamiliar and the new are assessed as having higher risk than the known.. How manufacturing sits versus perceived value creation in the pharmaceutical companies.In reality, pharmaceutical value creation comes from the development or acquisition of promising NCEs, and their ability to commercialise them.